Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data

作者：Roy S. Herbst, Juan Martín-Liberal, Emiliano Calvo, Nicolás Isambert, Johanna C. Bendell, Philippe A. Cassier, Jong‐Youl Jin, Gu Mi, Jessicca Rege, Luis Paz‐Ares · 发表于：Annals of Oncology · 年份：2017 · DOI：10.1093/annonc/mdx091.010 · 被引用次数：13 · 研究领域：Cancer Immunotherapy and Biomarkers、Cancer Diagnosis and Treatment、Colorectal Cancer Treatments and Studies